Quest Diagnostics India Launches “Satellite” Pathology Laboratory in Ghaziabad
Quest Diagnostics India Launches “Satellite” Pathology Laboratory in Ghaziabad
Satellite Pathology Lab in Indirapuram, Ghaziabad will address the growing demand of East Delhi and nearby markets like Greater Noida, Dadri, Meerut, Modinagar & Aligarh
Ghaziabad, March 11th , 2015: Quest Diagnostics (NYSE:DGX), the America’s leading provider of diagnostic testing, information and services, today announced the launch of its new Pathology laboratory in Indirapuram, Ghaziabad.
New 1000 sq. ft. satellite Pathology lab has capabilities of handling high quality tests that will serve to General Physicians, Gynecologists, Pediatricians etc., the satellite lab will provide patients in East Delhi and nearby markets like Greater Noida, Dadri, Meerut, Modinagar & Aligarh, access to world class testing facilities and will support main reference lab at Gurgaon by driving specialized tests.
Mr. Mukul Bagga, Managing Director, Quest Diagnostics India, said, “To set up a satellite pathology lab is a complex and a capital intensive process. We are glad that the physicians and residents of Ghaziabad, East Delhi & Noida can now access the world class quality of the pathology testing offered by Quest Diagnostics, close to their home. Today, increasingly patients and the treating physician need accurate, reliable and timely diagnostic insights in order to make the right treatment decision and it has been our constant endeavor to provide the latest specialized tests, with a minimum time lag. With the launch of our new lab we will also hope to serve the Pathology testing requirements amongst hospitals, nursing homes, private practitioners and consumers alike.
The new satellite Pathology Lab at Ghaziabad will also support the company’s vision of expanding access of Quest high quality services and will reduce the turnaround time for Pathology tests. The Satellite Pathology lab will have highest internal quality controls as well as external quality control process as per the Indian and International regulatory guidelines. The lab processes will be governed by Quest Diagnostics standard operating procedures to ensure that all patients receive the highest quality levels.
The company’s well known ‘Blue Print of Wellness’ will also be performed at this lab which provides consumers with an organ wise risk assessment. Additionally, physicians and patients will also be able to avail of pathologists both from India and US for case consultations.
In the past, Quest has been serving Ghaziabad through its Gurgaon based lab and enjoys high brand equity amongst hospitals, nursing homes and private practitioners.
Quest Diagnostics started operations in India in 2008, with its state-of-the art 65,000 sq. feet laboratory in Gurgaon, Haryana. Since then it has provided a broad spectrum of testing services in cardiology, gynecology, endocrinology, infectious diseases among others.
In India, Quest Diagnostics has been first to offer many path-breaking diagnostic testing services in cancer, such as Pap by liquid-based cytology for screening cervical cancer and Leumeta, proprietary plasma based test for leukemia. Earlier this year Quest Diagnostics India had announced its expansion to provide cancer diagnostics services to patients and oncologists in NCR through its full service laboratory in Gurgaon and esoteric testing laboratories based in the United States
About Quest Diagnostics
Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.
Comments are closed.